← All indications
Macular Degeneration
Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.
Subtype terms (5)
More specific conditions that are subtypes of Macular Degeneration in the MeSH hierarchy.
- Geographic Atrophy
52 drugs (14 approved, 38 experimental)
- Macular Edema
169 drugs (78 approved, 91 experimental)
- Stargardt Disease
19 drugs (5 approved, 14 experimental)
- Vitelliform Macular Dystrophy
2 drugs (1 approved, 1 experimental)
- Wet Macular Degeneration
68 drugs (28 approved, 40 experimental)
Drugs by status
Approved for this indication (7)
Phase 4 trials (15)
Phase 3 trials (44)
- abicipar pegol
- axitinib
- Anecortave
- alk-001
- vitamin e
- acetylcysteine
- beta carotene
- bevasiranib
- dorzolamide
- pegpleranib
- elamipretide
- hydralazine
- icosapent ethyl
- opt-302
- rostaporfin
- propranolol
- vegf receptor-fc fusion protein
- celecoxib
- acetylsalicylic acid
- squalamine
- alteplase
- tandospirone
- alprostadil
- zeaxanthin
- rgx-314
- glatiramer acetate
- clopidogrel
- timolol
- moxaverine
- perflutren protein-type a microspheres
- +14 more
Phase 2 trials (120)
- brimonidine
- alg-1001
- orlistat
- acadesine
- acetazolamide
- agn 211745
- mecamylamine
- bromfenac
- cnto 2476
- alpha-lipoic acid
- ct1812
- daclizumab
- doxycycline
- dimethyl fumarate
- disulfiram
- eculizumab
- emixustat
- n-(4-hydroxyphenyl)all-trans retinamide
- fosbretabulin
- tacrolimus
- hi-con1
- albumin (Human)
- levodopa
- carbidopa
- sonepcizumab
- lfg316
- Acrizanib
- ma09-hrpe
- ocriplasmin
- squalamine lactate
- +90 more
Phase 1 trials (53)
- adgvpedf.11d
- arc1905
- cgc-11047
- clg561
- betamethasone
- ds-7080a
- efalizumab
- jsm6427
- talaporfin
- mb-102
- metoclopramide
- retinostat
- fluorescein
- tk001
- vedolizumab
- volociximab
- aav2-sflt01
- autologous cd34+ cells
- autologous bone marrow derived mesenchymal cells
- frpe cells
- retinal pigment epithelial cells
- ketoconazole
- vegfr2
- vegfr1
- cm-082
- palomid 529
- vitamin a
- chlorhexidine
- ofloxacin
- fish oil
- +23 more
Other trials (37)
- vitamin d3
- tetracaine
- bone autograft
- egg
- vitis vinifera
- lampalizumab
- fiber
- folic acid
- cobalamin
- ketorolac
- platelet-rich plasma
- krill oil
- Olesoxime
- lidocaine
- proparacaine
- prulifloxacin
- tetravisc
- tocotrienol
- loteprednol
- tropicamide
- nicotinamide
- betahistine mesilate
- pistachios
- carotenoid
- walnut
- moxifloxacin
- pyridoxine
- riboflavin
- cocaine
- omega-3 fatty acids
- +7 more
Organizations
Organization Involved with Phase 4 Indications (71)
- Novelion Therapeutics
- Regeneron
- Bausch Health Companies
- Genentech
- Pfizer
- Novartis
- Bayer
- Ocular Therapeutix, Inc.
- Retina Research Institute, LLC
- Barcelona Macula Foundation
- Huazhong University of Science and Technology
- Central South University
- Baylor University
- California Retina Consultants
- University of London
- Harvard University
- Greater Houston Retina Research
- Hacettepe University
- Hospital Son Espases
- Institut de la Macula y la Retina
- Instituto de Olhos de Goiania
- McGill University
- Nagoya City University
- Nihon University
- Oklahoma State University
- Osaka University
- Retina Vitreous Associates of Florida
- Retinal Consultants of Arizona
- Seoul National University
- Singapore National Eye Centre
- +41 more
Organization Involved with Phase 3 Indications (77)
- Acucela Inc.
- Amgen
- Roche
- Bausch & Lomb
- Lupin
- Alcon
- Alkeus Pharmaceuticals, Inc.
- Allergan
- Biocad
- Chengdu Kanghong Biotech Co.,Ltd.
- Genaera Corporation
- Laboratorio Elea S.A.C.I.F. y A.
- MacuCLEAR, Inc.
- Miravant Pharmaceuticals
- Iveric Bio
- Parexel
- Apellis Pharmaceuticals, Inc.
- Mid-Atlantic Retina Consultations, Inc.
- NeoVista
- Rudolf Foundation Clinic
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Center for Complementary and Integrative Health (NCCIH)
- National Eye Institute (NEI)
- National Heart, Lung, and Blood Institute (NHLBI)
- Shahid Beheshti University of Medical Sciences
- University of Pennsylvania
- Medical University of Graz
- Canadian Retinal Trials Group
- Centre Hospitalier Intercommunal Creteil
- +47 more
Organization Involved with Phase 2 Indications (124)
- PPD
- Alimera Sciences
- Lineage Therapeutics
- Sirna Therapeutics
- Senju Pharmaceuticals
- Sirion Therapeutics
- AnewPharma
- Ocata Therapeutics
- Astellas
- Adverum Biotechnologies, Inc.
- CoMentis
- Grifols
- Sanofi
- Alexion
- Allegro Ophthalmics, LLC
- Aerie Pharmaceuticals
- Santen Inc.
- CHABiotech CO., Ltd
- Clearside Biomedical, Inc.
- GlaxoSmithKline
- Hamilton Health Sciences Corporation
- Hemera Biosciences
- Iconic Therapeutics, Inc.
- Ionis Pharmaceuticals, Inc.
- Lpath, Inc.
- Neurotech Pharmaceuticals
- Opthea Pty Ltd.
- Othera Pharmaceuticals
- PanOptica, Inc.
- Regenxbio Inc.
- +94 more
Organization Involved with Phase 1 Indications (38)
- Jerini
- Daiichi Sankyo
- Genzyme
- Biothera
- GenVec
- Innovent Biologics (Suzhou) Co. Ltd.
- Jiangsu T-Mab Biopharma Co.,Ltd
- Kyowa Hakko Kirin
- Light Sciences Oncology
- MediBeacon
- Oxford BioMedica
- Paloma Pharmaceuticals, Inc.
- Progen Pharmaceuticals
- Qilu Pharmaceutical Co., Ltd.
- Sunshine Lake Pharma Co., Ltd.
- Forsight Vision4
- Molecular Partners AG
- United States Army
- Nanjing Medical University
- University of Nebraska
- Capital Medical University
- Zhengzhou University
- University of Utah
- Tsinghua University
- Andover Eye Associates
- Sall Research Medical Center
- Pomeranian Medical University
- Lee's Pharmaceutical
- University of Tokyo
- VitreoRetinal Surgery, PA
- +8 more
Organization Involved with Other Experimental Indications (47)
- Kowa
- Aromtech Ltd.
- Bioheart, Inc.
- Chrysantis, Inc.
- Newtricious R&D BV
- Oraya Therapeutics, Inc.
- Physician Recommended Nutriceuticals
- United States Department of Agriculture
- Maastricht University
- Barnes Retina Institute
- Inje University
- Katholieke Universiteit Leuven
- Kumamoto University
- Loma Linda University
- Norwegian University of Science and Technology
- Retina Clinic, Sao Paulo, Brazil
- Russian Academy of Medical Sciences
- Tufts University
- University of Malaya
- University of Manchester
- West Virginia University
- Yale University
- Yonsei University
- University of Leipzig
- Mayo Clinic
- Mie University
- Prince of Songkla University
- University of Turku
- Affordance
- Vitreo-Retinal Associates, Michigan
- +17 more